Inhibiting CD36 for SARS-CoV-2 E-induced platelet activation and thrombosis

Inhibiting the transmembrane glycoprotein CD36 could help prevent SARS-CoV-2-associated thrombosis by blocking SARS-CoV-2 E protein-induced platelet activation via inhibition of the p38/MAPK signaling pathway.

Serum SARS-CoV-2 E levels were higher in non-severe COVID-19 patients than healthy individuals, with even higher levels in severe COVID-19 patients, and COVID-19 patients who tested positive for serum SARS-CoV-2 E had lower platelet counts, and higher activated partial thromboplastin time, prothrombin time, and levels of D-dimer and fibrinogen degradation products than serum SARS-CoV-2 E negative COVID-19 patients. ...